Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Huazhong University of Science and Technology349 enrolled

Overview

Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel trial.

This is a multicentre, open-label, randomized and parallel trial that will compare the efficacy and safety of basal insulin glargine combination with Exenatide bid vs. switching premix human insulin to aspart30 in type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin. Approximately 248 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms: once-daily insulin glargine + twice-daily exenatide + metformin; or twice-daily aspart 30 + metformin. Study treatment will continue for 24 weeks. The primary efficacy measure is the change in HbA1c at 24 weeks. The study consists of 3 periods: a 1-week screening (period A), a 12-week run-in period (period B) and a 24-week treatment period (period C).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

349

Conditions

Type 2 Diabetes Mellitus

Interventions

glargine + exenatideDRUG

glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)

aspart 30DRUG

aspart 30 ( subcutaneous injection, twice daily)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of informed consent * Type 2 diabetic patients receiving twice-daily premixed human insulin 30 therapy ≥ 30 U/d and metformin with maximum tolerated dosage (≤ 1500mg/d) * HbA1c \> 8.0 % and \< 11.0 % (HbA1c \> 7.0 % and \< 10.0% at randomization) * Men and women (non-pregnant and using a medically approved birth-control method) aged ≥ 18 and ≤ 70 years * BMI ≥ 23 and ≤ 35 kg/m2 Exclusion Criteria: * Type 1 diabetes or other specific types of diabetes * Pregnancy, preparation for pregnancy, lactation and women of child-bearing age incapable of effective contraception methods * Uncooperative subject because of various reasons * Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) \> twice the upper limits of normal * Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for male * Serious chronic gastrointestinal diseases * Edema * Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction * Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood pressure (DBP) ≥ 110mmHg * White blood count (WBC) \< 4.0×109/L or platelet count (PLT) \< 90×109/L，or definite anemia (Hb：\< 120g/L for male, \< 110g/L for female), or other hematological diseases * Endocrine system diseases, such as hyperthyroidism and hypercortisolism * Experimental drug allergy or frequent hypoglycemia * Psychiatric disorders, drug or other substance abuse * Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy * Stressful situations such as surgery, serious trauma and so on * Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease * Combined use of drugs effecting glucose metabolism such as glucocorticoid * Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria

Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology

Wuhan, Hubei, China

Outcomes

Primary Outcomes

the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.

Time frame: from baseline to 24-week endpoint

Secondary Outcomes

Change in HbA1c from baseline to 12 weeks endpoint

Time frame: from baseline to 12 weeks endpoint

The percentage of participants who achieved HbA1c ≤ 6.5% and < 7%

Time frame: 12 weeks and 24 weeks

Fasting blood glucose

Time frame: 12 weeks and 24 weeks

Daily insulin use

Time frame: baseline, 12 weeks and 24 weeks

Change in body weight

Time frame: from baseline to 12 and 24 weeks

The incidence and rate of hypoglycaemic events during the study

Time frame: baseline, 12 weeks and 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.